Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

108 0
  • IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)
  •  Antibody levels remained high after twelve months in … [+11239 chars]
    Read Full Story

Related Post